Microbicide Trials Network

  read more

The Center for Global Health Policy's "Science Speaks" blog examines a chart, titled "HIV Prevention Options Timeline," which "was part of AVAC Director Mitchell Warren's presentation at a Jhpiego-sponsored" event on Thursday, titled "The Present and the Future of HIV Prevention."

[Health-e]On the 27th April 2013 President Jacob Zuma honoured Wits Faculty of Health Sciences Professor Glenda Gray with South Africa's highest honour - the Order of Mapungubwe - for her life-saving research focusing on the mother to child transmission of HIV.

MEDIA RELEASE: On the 27th April 2013 President Jacob Zuma honoured Wits Faculty of Health Sciences Professor Glenda Gray with South Africa’s highest honour - the Order of Mapungubwe - for her life-saving research focusing on the mother to child transmission of HIV.

South Africa is home to the largest HIV epidemic in the world with a total of 5.6 million people living with HIV. Large-scale clinical trials evaluating combination methods of prevention and treatment are often prohibitively expensive and take years to complete.

Mathematical estimates of treatment outcomes can cut costs and provide faster delivery of preventative measures. South Africa is home to the largest HIV epidemic in the world with a total of 5.6 million people living with HIV. Large-scale clinical trials evaluating combination methods of prevention and treatment are often prohibitively expensive and take years to complete. In the absence of such ...

South Africa is home to the largest HIV epidemic in the world. Large-scale clinical trials evaluating combination methods of prevention and treatment are expensive and take years to complete. In the absence of such trials, mathematical models can help assess the effectiveness of different HIV intervention combinations, as demonstrated in a new study by Elisa Long and Robert Stavert from Yale ...

Richards, whose career focused on sexual and reproductive health, died April 4 in Washington, D.C., his home for many years.

[SciDev.Net]Kampala -Two European research bodies are collaborating on a clinical research fellowship scheme to train biomedical students in Sub-Saharan Africa, with the first open call for applications expected later this year.

[KAMPALA] Two European research bodies are collaborating on a clinical research fellowship scheme to train biomedical students in Sub-Saharan Africa, with the first open call for applications expected later this year.

A reformulated version of an anti-HIV gel developed for vaginal use was found safe and acceptable by HIV-negative men and women who used it rectally, according to a Phase I clinical trial published today in PLOS ONE.

( Microbicide Trials Network ) A reformulated version of an anti-HIV gel developed for vaginal use was found safe and acceptable by HIV-negative men and women who used it rectally, according to a Phase I clinical trial published today in PLOS ONE. The study, led by researchers with the US National Institutes of Health-funded Microbicide Trials Network, tested a reduced glycerin formulation of ...

( Albert Einstein College of Medicine ) Researchers at Albert Einstein College of Medicine of Yeshiva University have been awarded a $12 million grant from the National Institutes of Health to develop a drug-impregnated intravaginal ring to prevent HIV infection in women.

Researchers at Albert Einstein College of Medicine of Yeshiva University have been awarded a $12 million grant from the National Institutes of Health (NIH) to develop a drug-impregnated intravaginal ring to prevent HIV infection in women.

The failure of one of the largest trials yet conducted of HIV drug-based prevention methods poses questions for how to turn vaginal microbicides and oral pre-exposure prophylaxis (PrEP) into methods people can actually use, the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta heard today. The VOICE trial randomised 5029

The failure of one of the largest trials yet conducted of HIV drug-based prevention methods poses questions for how to turn vaginal microbicides and oral pre-exposure prophylaxis (PrEP) into methods people can actually use, the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta heard today. The VOICE trial randomised 5029

( Microbicide Trials Network ) A major HIV prevention trial found daily use of a product was not the right approach for young, unmarried African women. Of three products tested in VOICE -- tenofovir gel, oral tenofovir and oral Truvada -- none was effective among the 5,029 women in the trial; most participants did not use them daily as recommended. Moreover, young, single women were least likely ...

PrEP Strategies Remain Valuable Prevention Tool, says AVAC NEW YORK, March 4, 2013 /PRNewswire-USNewswire/ -- Results from a large-scale HIV prevention trial among African women known as VOICE (Vaginal and Oral Interventions to Control the Epidemic) provide an urgent reminder that...

PrEP Strategies Remain Valuable Prevention Tool, says AVACNEW YORK, March 4, 2013 /PRNewswire-USNewswire/ -- Results from a large-scale HIV prevention trial among African women known as VOICE (Vaginal and Oral Interventions to Control the Epidemic) provide an urgent reminder that products must meet the needs of the people using them. While disappointing, the results lend new urgency and ...

( Burness Communications ) Across-the-board cuts to US R&D programs could have a devastating impact on efforts to develop new drugs for tuberculosis and HIV/AIDS, the world's first malaria vaccine, and other vital global health products in development, according to a new report from a coalition of nonprofit groups focused on advancing innovation to save lives.